MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 576672 | Name: Indinavir monohydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Indinavir monohydrate is a potent and specific HIV protease inhibitor that appears to have good oral bioavailability.

Chemical Structure

Indinavir monohydrate
Indinavir monohydrate
CAS#180683-37-8 (hydrate)

Theoretical Analysis

MedKoo Cat#: 576672

Name: Indinavir monohydrate

CAS#: 180683-37-8 (hydrate)

Chemical Formula: C36H49N5O5

Exact Mass: 0.0000

Molecular Weight: 631.82

Elemental Analysis: C, 68.44; H, 7.82; N, 11.08; O, 12.66

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
150378-17-9 (free base) 157810-81-6 (sulfate) 180683-37-8 (hydrate)
Synonym
Indinavir hydrate; Indinavir monohydrate
IUPAC/Chemical Name
(S)-1-((2S,4R)-4-benzyl-2-hydroxy-5-(((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)amino)-5-oxopentyl)-N-(tert-butyl)-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide hydrate
InChi Key
XTYSXGHMTNTKFH-BDEHJDMKSA-N
InChi Code
InChI=1S/C36H47N5O4.H2O/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43;/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45);1H2/t28-,29+,31+,32-,33+;/m1./s1
SMILES Code
O.CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc3ccccc3)C(=O)N[C@@H]4[C@H](O)Cc5ccccc45
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 631.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Barrail-Tran A, Taburet AM, Poirier JM; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique. [Evidence-based therapeutic drug monitoring for indinavir]. Therapie. 2011 May-Jun;66(3):239-46. doi: 10.2515/therapie/2011035. Epub 2011 Aug 9. Review. French. PubMed PMID: 21819808. 2: Cressey TR, Plipat N, Fregonese F, Chokephaibulkit K. Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings. Expert Opin Drug Metab Toxicol. 2007 Jun;3(3):347-61. Review. PubMed PMID: 17539743. 3: Boyd M. Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role? Expert Opin Pharmacother. 2007 May;8(7):957-64. Review. PubMed PMID: 17472541. 4: Fernández JM, Robles JE, Regojo JM, López J, Sánchez D, Arocena J, Rosell D, Zudaire JJ, Berián JM. [Renal lithiasis due to indinavir]. Rev Med Univ Navarra. 2002 Jul-Sep;46(3):28-32. Review. Spanish. PubMed PMID: 12685114. 5: García-Silva J, Almagro M, Peña-Penabad C, Fonseca E. Indinavir-induced retinoid-like effects: incidence, clinical features and management. Drug Saf. 2002;25(14):993-1003. Review. PubMed PMID: 12408731. 6: Rayner CR, Galbraith KJ, Marriott JL, Duncan GJ. A critical evaluation of the therapeutic range of indinavir. Ann Pharmacother. 2002 Jul-Aug;36(7-8):1230-7. Review. PubMed PMID: 12086558. 7: Wu DS, Stoller ML. Indinavir urolithiasis. Curr Opin Urol. 2000 Nov;10(6):557-61. Review. PubMed PMID: 11148725. 8: Famularo G, Di Toro S, Moretti S, De Simone C. Symptomatic crystalluria associated with indinavir. Ann Pharmacother. 2000 Dec;34(12):1414-8. Review. PubMed PMID: 11144699. 9: Benson JO, McGhee K, Coplan P, Grunfeld C, Robertson M, Brodovicz KG, Slater E. Fat redistribution in indinavir-treated patients with HIV infection: A review of postmarketing cases. J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):130-9. Review. PubMed PMID: 11103043. 10: The choice of HIV protease inhibitor: indinavir is currently the best option. Prescrire Int. 1999 Apr;8(40):55-60. Review. PubMed PMID: 10848067. 11: Gagnon RF, Alli AI, Watters AK, Tsoukas CM. Indinavir crystalluria. Kidney Int. 2006 Dec;70(12):2047. Review. PubMed PMID: 17136127. 12: Florence E, Schrooten W, Verdonck K, Dreezen C, Colebunders R. Rheumatological complications associated with the use of indinavir and other protease inhibitors. Ann Rheum Dis. 2002 Jan;61(1):82-4. Review. PubMed PMID: 11779768; PubMed Central PMCID: PMC1753893. 13: Youle M. Optimizing indinavir regimens. HIV Med. 2000 Jul;1 Suppl 2:7-11. Review. PubMed PMID: 11737366. 14: Plosker GL, Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs. 1999 Dec;58(6):1165-203. Review. PubMed PMID: 10651394. 15: Perazella MA, Kashgarian M, Cooney E. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clin Nephrol. 1998 Sep;50(3):194-6. Review. PubMed PMID: 9776425. 16: Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci. 1997 Aug;19(4):159-75. Review. PubMed PMID: 9297727. 17: Chefchaouni MC, Thiounn N, Flam T, Zerbib M, Debré B. [Urinary calculi and indinavir sulfate in patients with HIV infection. Apropos of 4 cases]. J Urol (Paris). 1997;103(1-2):35-6. Review. French. PubMed PMID: 9765778. 18: Lacy MK, Abriola KP. Indinavir: a pharmacologic and clinical review of a new HIV protease inhibitor. Conn Med. 1996 Dec;60(12):723-7. Review. PubMed PMID: 9018893.

View History

Indibulin

Indibulin

Featured